Figure 6. Intratumoral viral DNA replication, but not tumor specificity of the used virus, determines the efficacy of ODC.

s.c. KLN-HA, CMT-OVA, and Hepa1-6-OVA tumors were injected with 1 × 10⁹ infectious particles of hTert-Ad (tumor-specific replication) or Ad5-WT (unspecific replication). After 3 days, DC vaccination against the corresponding model antigen was performed. Untreated mice and rdAd treatment served as controls. After 14 days, ELISpot analyses were performed. Shown is tumor antigen–specific response; antigen-specific responses in the respective hTert-Ad groups were defined as 100% (n = 4 per group, 2 independent experiments).